Biotecnología
Pathway screening

[ Cerrar ]

thrombotarget

 

 thrombotargets

   
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
       

  
 

Biotech solutions

We have developed a novel and innovative approach to traditional High Throughput Screening that will change the way lead compounds are identified in the areas of Hemostasis, Atherosclerosis, Aging and Thrombosis.

We are an emerging biotech group pioneering the development of a new generation of High Throughput Screening (HTS) platforms (BioPlatformScreenTM) useful to discover innovative drugs for the treatment of prevalent and relevant diseases such as hemorrhagic and thrombotic disorders (acute myocardial infarction, angina and stroke).

Contact

www.Thrombotargets.com
General: info@thrombotargets.com



Search keys:     haemostatic     haemostatic agent     haemostatic drug     hemostatic     hemostatic agent     hemostatic agents     hemostatic drug 

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:


Therapeutics
Product candidates
Biotech solutions
BioPlatformScreen
Other services
© 2006 - Thrombotargets Corp. All rights reserved - coagulation - treatment